Episode Ten: The Impact of AI and a New Standard in Clinical Trials
Join us for the next episode of AI Uncovered, featuring Michael Penlington, an expert in life sciences. Michael has led vaccine development and clinical reporting at Novartis and held senior roles in scientific and global medical writing at GSK. Currently, he serves as Director of Digital Clinical Development Solutions at Nurocor.
In this episode, Tim and Michael explore the impact of AI on clinical development, discussing current trends, challenges, and the driving forces behind pharma’s digital transformation. Michael shares valuable insights from his career, including his experience with new standards like ICH M11 and their influence on study design, clinical trial management, and data management. As a key figure at the intersection of digital technology and life sciences, Michael offers a forward-looking perspective on the future of clinical processes.
“…we can massively speed up the clinical trials. If we can design trials that will basically engage people who are most at risk of disease, that will be a game changer.”
Listen and subscribe to AI Uncovered on all major podcast platforms:
About AI Uncovered
AI Uncovered is our podcast, made for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.
With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization.
Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product.
The post AI Uncovered with Michael Penlington (The Impact of AI and a New Standard in Clinical Trials) appeared first on Yseop.
